Impact BioMedical, Inc.
About: Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Employees: 8
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
29% more capital invested
Capital invested by funds: $59.1K [Q3] → $76.1K (+$17K) [Q4]
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
13% more funds holding
Funds holding: 8 [Q3] → 9 (+1) [Q4]
0.2% more ownership
Funds ownership: 0.26% [Q3] → 0.46% (+0.2%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for IBO.
Financial journalist opinion






